

Barcelona, February 3<sup>rd</sup> 2021

## **OTHER RELEVANT INFORMATION**

### **Almirall announces Gianfranco Nazzi as new CEO**

In accordance with Securities Markets Law approved Almirall, S.A. (“Almirall”) announce the following:

The Board of Directors have approved the appointment of Mr. Gianfranco Nazzi as CEO and Executive Director of the Board of Directors effective May 1, 2021.

Mr. Nazzi joins Almirall from Teva Pharmaceuticals Industries Ltd, where he has most recently been serving as Executive Vice President of the International Markets Region and as a member of the Teva Executive Committee. While at Teva over the past seven years, he has held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. He held the position of Senior Vice President Specialty Medicines Europe and President and CEO Growth Markets Region. Prior to Teva Mr. Nazzi held a variety of senior positions in Astra Zeneca, GSK and Eli Lilly in commercial and General Management roles based in the UK, Italy, Serbia and the US.

Please find below Press Release sent to media.

Yours sincerely,

Pablo Divasson del Fraile  
Investor Relations Department  
[investors@almirall.com](mailto:investors@almirall.com)

# Almirall announces Gianfranco Nazzi as new CEO

- **Gianfranco Nazzi brings broad international experience from a distinguished career in Pharma**
- **Mr. Nazzi will join Almirall as Chief Executive Officer on May 1, 2021**

**Almirall, S.A. (BME:ALM)**, a global biopharmaceutical company focused on Medical Dermatology based in Barcelona, announced today that the Board of Directors have approved the appointment of Mr. Gianfranco Nazzi as CEO and Executive Director of the Board of Directors effective May 1, 2021.

Mr. Nazzi joins Almirall from Teva Pharmaceuticals Industries Ltd, where he has most recently been serving as Executive Vice President of the International Markets Region and as a member of the Teva Executive Committee. While at Teva over the past seven years, he has held roles of increasing responsibility and geographic scope based in Israel and the Netherlands. He held the position of Senior Vice President Specialty Medicines Europe and President and CEO Growth Markets Region. Prior to Teva Mr. Nazzi held a variety of senior positions in Astra Zeneca, GSK and Eli Lilly in commercial and General Management roles based in the UK, Italy, Serbia and the US.

*"I'm very pleased to announce that the Board of Directors have agreed to appoint Gianfranco Nazzi. Mr. Nazzi is a trusted leader in the Pharma industry and brings with him a wealth of experience in areas key to the success and growth of Almirall, in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level",* said **Jorge Gallardo**, Chairman of the Board and President of Almirall.

*"I am really excited to join Almirall and its talented team of professionals. The company's focus on putting patients at the center of all that they do is inspiring and I am sure that I will be able to continue to support them and provide them with novel and value added solutions and treatments to improve their lives. I am committed to this mission and I know that, together with the team, we will achieve great milestones in the near future",* stated **Gianfranco Nazzi**.

Gianfranco Nazzi is Italian and holds a degree in Economics and Banking Sciences from the University of Udine and a Master's Degree of Business Administration from the Bocconi University of Milan.

Mr. Nazzi will take over the CEO duties from Mike McClellan, who at the beginning of the year was appointed interim CEO in addition to his role as CFO after the company's former Chief Executive Officer, Peter Guenter, left Almirall on December 31<sup>st</sup> to pursue other professional endeavors.

## About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit [almirall.com](https://www.almirall.com)

**Almirall Media contact:**

Tinkle

Pilar Colomer

[pcolomer@tinkle.es](mailto:pcolomer@tinkle.es)

Phone: (+34) 93 93 545 0861

**Almirall Corporate Communications contact:**

Mar Ramírez

[mar.ramirez@almirall.com](mailto:mar.ramirez@almirall.com)

Phone: (+34) 659 614 173

**Almirall Investors' relations contact:**

Pablo Divasson del Fraile

[pablo.divasson@almirall.com](mailto:pablo.divasson@almirall.com)

Phone.: (+34) 932 913 087

**Legal warning**

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to historical information, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication [click here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre, 151, 08022, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: [dpo.global@almirall.com](mailto:dpo.global@almirall.com). PRNewswire is the Agency that licenses your personal data according to their privacy policy: <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.